Peptides Similar to Pegcetacoplan
Compare Pegcetacoplan with related peptides and alternatives
📌TL;DR
- •2 similar peptides identified
- •Zilucoplan: Both are peptide-based complement inhibitors with subcutaneous administration options. Both are FDA-approved for complement-mediated diseases. Both were engineered from peptide discovery platforms.
- •Rusfertide: Both are synthetic peptides in the Immune category with subcutaneous administration for hematologic conditions.
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| Pegcetacoplan (current) | - | - |
| Zilucoplan | Both are peptide-based complement inhibitors with subcutaneous administration options. Both are FDA-approved for complement-mediated diseases. Both were engineered from peptide discovery platforms. | Different complement targets (C3 vs C5), different indications (PNH/GA vs gMG), different molecular architectures (PEGylated cyclic vs macrocyclic), different dosing (twice weekly vs daily). |
| Rusfertide | Both are synthetic peptides in the Immune category with subcutaneous administration for hematologic conditions. | Completely different mechanisms: pegcetacoplan inhibits complement C3 for hemolysis control, while rusfertide mimics hepcidin for iron restriction in polycythemia vera. |
ZilucoplanBoth are peptide-based complement inhibitors with subcutaneous administration options. Both are FDA-approved for complement-mediated diseases. Both were engineered from peptide discovery platforms.
Differences
Different complement targets (C3 vs C5), different indications (PNH/GA vs gMG), different molecular architectures (PEGylated cyclic vs macrocyclic), different dosing (twice weekly vs daily).
Advantages
Broader complement inhibition at C3 level, addresses both intravascular and extravascular hemolysis, dual-indication approval.
Disadvantages
Broader immunosuppression, larger molecule, requires infusion pump for PNH dosing.
RusfertideBoth are synthetic peptides in the Immune category with subcutaneous administration for hematologic conditions.
Differences
Completely different mechanisms: pegcetacoplan inhibits complement C3 for hemolysis control, while rusfertide mimics hepcidin for iron restriction in polycythemia vera.
Advantages
FDA-approved with dual-indication portfolio; addresses complement-mediated hemolysis across pathways.
Disadvantages
Broader immunosuppression than the targeted iron-restriction mechanism of rusfertide.
Complement Inhibitors Related to Pegcetacoplan#
Pegcetacoplan is a C3-targeted complement inhibitor with two approved indications. The complement system can be targeted at multiple points, and each level of inhibition has distinct therapeutic implications. The most relevant comparisons are with C5 inhibitors (eculizumab, ravulizumab, zilucoplan), the C5 peptide inhibitor for GA (avacincaptad pegol), and emerging oral complement inhibitors.
Eculizumab (Soliris)#
Eculizumab is a humanized monoclonal antibody targeting C5, approved for PNH, aHUS, gMG, and NMOSD. It was the first complement inhibitor to reach the market (2007) and established the therapeutic paradigm for complement-mediated diseases.
Mechanism comparison: Eculizumab blocks C5 cleavage, preventing MAC formation and controlling intravascular hemolysis. However, it cannot prevent C3b opsonization of PNH red blood cells, leading to persistent extravascular hemolysis in many patients. Pegcetacoplan blocks at C3, upstream of this limitation.
Clinical evidence: The PEGASUS trial directly compared the two drugs and demonstrated pegcetacoplan's superiority in hemoglobin improvement (adjusted mean difference 3.84 g/dL, P<0.001).
| Parameter | Pegcetacoplan | Eculizumab |
|---|---|---|
| Target | C3 | C5 |
| Hemolysis control | Intravascular + extravascular | Intravascular only |
| Route (PNH) | SC (self-infusion) | IV (infusion center) |
| Frequency (PNH) | Twice weekly | Every 2 weeks |
| MW | ~43.5 kDa | ~148 kDa |
| Approval year | 2021 | 2007 |
Ravulizumab (Ultomiris)#
Ravulizumab is an engineered anti-C5 antibody with a longer half-life than eculizumab, allowing dosing every 8 weeks. Like eculizumab, it only addresses intravascular hemolysis in PNH.
Key differences: Ravulizumab offers less frequent IV infusions but still requires a healthcare setting. Pegcetacoplan can be self-administered at home. Ravulizumab does not address extravascular hemolysis.
Zilucoplan (Zilbrysq)#
Zilucoplan is a macrocyclic peptide C5 inhibitor approved for gMG. Both are peptide-based complement inhibitors but target different components and different diseases.
Key differences: Zilucoplan is smaller (~3.5 kDa), self-injected daily via simple SC injection for gMG. Pegcetacoplan is larger (~43.5 kDa) and requires infusion pump delivery for PNH. They target different complement components (C5 vs C3) and different indications.
Avacincaptad Pegol (Izervay)#
Avacincaptad pegol is a PEGylated anti-C5 aptamer approved for geographic atrophy (August 2023), making it the second approved GA treatment after Syfovre.
Mechanism comparison: Both are intravitreal complement inhibitors for GA, but pegcetacoplan targets C3 while avacincaptad pegol targets C5. This difference parallels the PNH landscape, where C3 inhibition provides broader coverage.
Clinical comparison: No head-to-head trial exists. Indirect comparison:
- Pegcetacoplan (OAKS/DERBY): 19-22% reduction in GA growth at 24 months (monthly)
- Avacincaptad pegol (GATHER1/GATHER2): ~14-18% reduction in GA growth
Iptacopan (Fabhalta)#
Iptacopan is an oral factor B inhibitor approved for PNH (December 2023). It represents the next frontier in complement inhibition -- an oral small molecule that can be taken at home without injections.
Key differences: Iptacopan is an oral pill (twice daily), offering maximum convenience over both SC pegcetacoplan and IV C5 inhibitors. As a factor B inhibitor, it targets the alternative pathway specifically rather than blocking all three pathways at C3.
Summary Comparison#
| Feature | Pegcetacoplan | Eculizumab | Ravulizumab | Zilucoplan | Avacincaptad Pegol |
|---|---|---|---|---|---|
| Target | C3 | C5 | C5 | C5 | C5 |
| Type | PEGylated cyclic peptide | mAb | Engineered mAb | Macrocyclic peptide | PEGylated aptamer |
| Route | SC or IVT | IV | IV | SC | IVT |
| Self-admin | Yes (SC) | No | No | Yes | No |
| PNH | Approved | Approved | Approved | No | No |
| GA | Approved | No | No | No | Approved |
| gMG | No | Approved | Approved | Approved | No |
Related Reading#
Frequently Asked Questions About Pegcetacoplan
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer